Psoriasis

We are focused on making a difference for the millions of people who live with psoriasis.

Psoriasis is a common, chronic, immune-mediated inflammatory disorder with primary involvement of the skin. It is commonly considered the most prevalent autoimmune disease in the world, affecting nearly 3 percent of the world’s population, or approximately 125 million people worldwide1, and approximately 2.6 percent of the U.S. population, or approximately 8.4 million people.2 This skin condition affects men and women of all ages and ethnicities. Psoriasis signs and symptoms can vary, but may include red patches of skin covered with silvery scales; dry, cracked skin that may bleed; and thickened, pitted or ridged nails.

A source of significant physical discomfort.

Approximately 80 to 90 percent of psoriasis patients have plaque psoriasis, and approximately 20 percent of psoriasis patients have moderate-to-severe disease affecting more than 3 percent of their body surface area. Plaque psoriasis is a recurring inflammatory skin disease characterized by itchy skin spots, red patches and thick flaky lesions.3 These areas are often painful and may crack and bleed. People living with psoriasis often face a heavy disease burden and may experience significant physical discomfort, including severe itching and pain.

Additional treatment options are needed.

Plaque psoriasis has historically been difficult to treat, and many of the available therapies are not effective for all patients. Biologic tumor necrosis factor-α (TNF) inhibitors are standard first-line therapy for patients with moderate-to-severe chronic plaque psoriasis. However, only about 10 percent of patients with moderate-to-severe disease use biologics.5

Despite the advances in the treatment of psoriasis, approximately half of patients with moderate-to-severe plaque psoriasis are unsatisfied with their current treatment options.6 Given that currently available treatments are not the right fit for all patients, new treatment options that can help patients successfully manage their condition are needed.

  • 1 http://www.ifpa-pso.com/.
  • 2 Decision Resources, Immune and Inflammatory Disorders Study, Psoriasis, October 2014.
  • 3 Psoriasis.com. Accessed on April 18, 2016.
  • 4 National Psoriasis Foundation website – Psoriasis Severity. Accessed January 2015.
  • 5 Decision Resources, Immune and Inflammatory Disorders Study, Psoriasis, October 2014. U.S. Sales of Biologics for Psoriasis.
  • 6 Armstrong et al., JAMA 2013 data from 2003-2011. Represents percent of moderate-to-severe plaque psoriasis patients.